Law360, New York (July 06, 2004, 12:00 AM ET) -- Mylan Laboratories has agreed to pay $9 million to Tapestry Pharmaceuticals Inc. and Australia-based Mayne Group Ltd's U.S. unit to settle a patent lawsuit over the cancer treatment paclitaxel.
Mylan, the largest maker of generic drugs in the U.S., said the payment will end a lawsuit pending in federal court in Pittsburgh. Under the settlement, Mylan will have a paid-up license to sell paclitaxel under Mayne's patents.
“The parties will promptly file stipulations of dismissal with prejudice with the U.S. District Court for the Western District...
Mylan Pays $9M To Settle Paclitaxel Patent Suit
To view the full article, take a free trial now.
